Saint Luke's Cancer Institute.

Clinical research site in Kansas City, Missouri · 4401 WORNALL RD, KANSAS CITY, MO 64111-3220 · (816) 932-3300 · Website

Part of Saint Luke's Cancer Institute

As of July 2026, 13 paid clinical trials are recruiting at Saint Luke's Cancer Institute. in Kansas City, Missouri. Active studies at this site cover conditions such as Breast Cancer, Breast Neoplasms and Metastatic Breast Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Saint Luke's Cancer Institute. (13)

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

for Pancreatic Cancer

29 locations incl. Los Angeles

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT07252232·Phase 3·Recruiting·Listed Nov 2025

Apply to this trial

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

for Breast Neoplasms

116 locations incl. Anchorage

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07174336·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

for Breast Neoplasms

59 locations incl. Gilbert

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06966700·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

for Breast Neoplasms

42 locations incl. Chandler

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06312176·Phase 3·Recruiting·Listed Mar 2024

Apply to this trial

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

for Colorectal Cancer

32 locations incl. Birmingham

Sponsor: Takeda

Sex: All·Age: 18+

Code: NCT06562543·Phase 4·Recruiting·Listed Aug 2024

Apply to this trial

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

for Breast Neoplasms

38 locations incl. Hot Springs

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT06926868·Phase 2, Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

for Breast Cancer

24 locations incl. Los Angeles

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT05768139·Phase 1, Phase 2·Recruiting·Listed Mar 2023

Apply to this trial

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

for Metastatic Breast Cancer

31 locations incl. Scottsdale

Sponsor: LeonaBio

Sex: All·Age: 18+

Code: NCT05696626·Phase 3·Recruiting·Listed Jan 2023

Apply to this trial

A Phase 1/1b Study of IAM1363 in HER2 Cancers

for HER2 Mutation-Related Tumors

29 locations incl. La Jolla

Sponsor: Iambic Therapeutics, Inc

Sex: All·Age: 18+

Code: NCT06253871·Phase 1·Recruiting·Listed Feb 2024

Apply to this trial

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

for Metastatic HER2-positive Breast Cancer

45 locations incl. Phoenix

Sponsor: Jazz Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06435429·Phase 3·Recruiting·Listed May 2024

Apply to this trial

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

for Hormone Receptor Positive HER-2 Negative Breast Cancer

34 locations incl. Birmingham

Sponsor: Puma Biotechnology, Inc.

Sex: All·Age: 18+

Code: NCT06369285·Phase 2·Recruiting·Listed Apr 2024

Apply to this trial

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

for Breast Cancer

22 locations incl. Duarte

Sponsor: Celcuity Inc

Sex: All·Age: 18+

Code: NCT06757634·Phase 3·Recruiting·Listed Jan 2025

Apply to this trial

Integrated Cancer Repository for Cancer Research

for Pancreatic Cancer

42 locations incl. Greenwood Village

Sponsor: University of Nebraska

Sex: All·Age: 19 - 110·Accepts healthy volunteers

Code: NCT02012699·Recruiting·Listed Dec 2013

Apply to this trial

Explore more

Paid clinical trials in Kansas City, MO · Missouri clinical trials

Saint Luke's Cancer Institute.

Recruiting clinical trials at Saint Luke's Cancer Institute. (13)

More research sites in Kansas City

Explore more